Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00785915 · ClinicalTrials.gov registry record · Phase 1

AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects

A Phase 1 study, sponsored by AstraZeneca.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target

NCT00785915 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00785915, a Phase 1 study, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target

Study Summary

This is a Phase I randomized double-blind, placebo-controlled, single and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of AZD6765 in healthy male and female Japanese and Caucasian subjects

Interventions

  • DRUG Placebo
  • DRUG AZD6765

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2008-11
Est. Completion 2009-03
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

What the Registry Record Tells You About NCT00785915

The ClinicalTrials.gov registry entry for NCT00785915 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT00785915 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00785915 about?

NCT00785915 is a clinical study titled "AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects". This is a Phase I randomized double-blind, placebo-controlled, single and multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of AZD6765 in healthy male and female Japanese and Caucasian subjects

What is the current status of trial NCT00785915?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2008-11. Estimated completion is 2009-03.

What interventions are being tested in trial NCT00785915?

The interventions under investigation include: Placebo (DRUG), AZD6765 (DRUG).

Who is sponsoring clinical trial NCT00785915?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.